Loading...
•
Jun 30, 2021
4DMT Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided operational highlights.
Key Takeaways
4D Molecular Therapeutics reported a total revenue of $14.6 million for the quarter ended June 30, 2021, compared to $3.6 million for the quarter ended June 30, 2020. Net loss was $7.6 million for the quarter ended June 30, 2021, as compared to $15.2 million for the quarter ended June 30, 2020. Cash and cash equivalents were $243.7 million as of June 30, 2021.
Initiated the expansion of cGMP manufacturing facilities to support commercial-scale production of clinical product candidates.
Completed cGMP manufacturing of primate-evolved targeted vectors with three different clinical product candidates.
Appointed Carolyne Zimmermann as Chief Business Officer.
Appointed Nadine Greiner, Ph.D., as Chief Human Resources Officer.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4DMT expects to announce clinical data from each of its three ongoing clinical programs and to initiate clinical development with product candidates in wet AMD and cystic fibrosis by the end of this year. We expect cash and cash equivalents to be sufficient to fund operations into the second half of 2023.
Positive Outlook
- Initial clinical data from the Phase 1/2 clinical trial of 4D-310 in Fabry disease expected in the fourth quarter of 2021
- Initial clinical activity data from the Phase 1/2 clinical trial of 4D-125 in XLRP expected in the fourth quarter of 2021
- Initial clinical activity data from the Phase 1 clinical trial of 4D-110 in choroideremia expected in the fourth quarter of 2021
- Initiation of a clinical trial with 4D-150 in wet AMD expected in the fourth quarter of 2021
- Initiation of a clinical trial with 4D-710 in cystic fibrosis lung disease expected in the fourth quarter of 2021